Skip to main content
SpringerLink
Log in

The cardiovascular and central nervous system effects in the human of U-62066E

A selective opioid receptor agonist

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The cardiovascular and central nervous system effects of the kappa opioid receptor agonist U-62066E were investigated in ten normal male subjects who received U-62066E or placebo with low or high dose naloxone in a randomized, double blind study.

Blood pressure and heart rate in the supine and standing position, plasma adrenaline and noradrenaline, regional Doppler blood velocity indices and psychometric assessments were recoreded for 1.25 h before and 6 h following injection. U-62066E caused sedation and dysphoria but no euphoria.

Plasma noradrenaline was increased by U62066E when compared with basal levels. This action of U62066E was prevented by high but not low dose naloxone.

U-62066E had no significant effect on blood pressure, heart rate or regional blood flow indices in the vessels studied and no effect on plasma adrenaline levels.

Since U62066E at a dose known to have marked kappa effects was not found to influence cardiovascular indices our results do not support a major role for kappa opioids in the control of the circulation. However, U62066E may influence noradrenaline release or clearance and cause sedation and psychotomimetic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Medvedev OS, Martynova ER, Hoque AM (1988) Effects of Mu- and Delta- opiate receptor agonists on systemic and regional haemodynamics in conscious rats. In: Stumpe KO, Kraft K, Faden AI (eds) Opioid peptide and blood pressure control. Springer, Berlin Heidelberg New York, pp 159–167

    Google Scholar 

  2. Zelis R, Mansour EJ, Capone RJ, Mason DT (1974) The cardiovascular effects of norphine. J Clin Invest 54: 1247–1258

    Google Scholar 

  3. Lowenstein E, Hallowell P, Levine FH, Daggett WM, Austen WG, Laver MB (1969) Cardiovascular responses to large doses of intravenous morphine in man. N Engl J Med 281: 1389–1393

    Google Scholar 

  4. Drew JH, Dripps RD, Comroe JH (1946) Clinical studies on morphine II. The effect of morphine upon the circulation of man and upon the circulatory and respiratory responses to tilting. Anaesthesiol 7: 44–61

    Google Scholar 

  5. Rubin PC, McLean K, Reid JL (1983) Endogenous opioids and baroreflex control in man. Hypertension 5: 535–538

    Google Scholar 

  6. Pasanisi F, Sloan L, Rubin PC (1985) Cardiovascular properties of methkephamid a delta opioid agonist: U-62066E. J Pharmacol Exp Ther 240: 128–131

    Google Scholar 

  7. Frederichson RLA, Smithwick EK, Shuman R, Bemis KG (1981) Metkephanid, a systematically active analogue of methionine enkephalin with potent opioid receptor activity. Science 211: 603–605

    Google Scholar 

  8. Hardy GW, Sang PY, Simpkin DSA, Wilkinson S, Follenfant RL, Lowe LA, Smith TW (1988) Peripherally acting enkephalin analogue 1 polar pentapeptides. J Med Chem 31: 960–966

    Google Scholar 

  9. Cohen AF, Harkin N, Posner J (1990) Cardiovascular effects of a novel enkephalin analogue 443C81 in humans. J Cardiovasc Pharmacol 16: 455–460

    Google Scholar 

  10. Posner J, Moody SG, Peck AW, Rutter D, Telekes A (1990) Analgesic, central, cardiovascular and endocrine effects of the enkephalin analogue Tyr-D-Arg-Gly-Phe-(NO2)-Pro-NH2 (443C81) in healthy volunteers. Eur J Clin Pharmacol 38: 213–218

    Google Scholar 

  11. Rubin PC (1984) Opioid peptides in blood pressure regulation in man. Clin Sci 66: 625–630

    Google Scholar 

  12. Lahti RA, Michelson MM, McCall JM, Von Voigtlander PF (1985) [3H] U-69593: a highly selective ligand for the opioid K-receptor. Eur J Pharmacol 109: 281–284

    Google Scholar 

  13. Peters GR, Ward NJ, Antal EF, Lai DY, DeMaar EW (1987) Diuretic actions in man of a selective kappa opioid agonist: U-62066E. J Pharmacol Exp Ther 240: 128–131

    Google Scholar 

  14. Rimoy GH, Bhaskar NK, Wright DM, Rubin PC (1991) Mechanism of diuretic action of U-62066E — a kappa opioid receptor agonist in the human. Br J Clin Pharmacol 32: 611–615

    Google Scholar 

  15. MacDonald IA, Lake DM (1985) An improved technique for extracting catecholamines from body fluids. J Neuroscience Meth 13: 239–249

    Google Scholar 

  16. Preston KL, Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264: 813–823

    Google Scholar 

  17. Babkoff H, Caspy T, Mikulincer M (1991) Subjective sleepiness ratings: the effects of sleep deprivation, circadian rhythmicity and cognitive performance. Sleep 14: 534–539

    Google Scholar 

  18. Hastie SJ, Howie CA, Whittle MJ, Rubin PC (1988) Daily variability of umbilical and lateral uterine wall artery blood velocity waveform measurements. Br J Obstet Gynaecol 95: 571–574

    Google Scholar 

  19. Rimoy GH, Bhaskar NK, Rubin PC (1991) Reproducibility of Doppler Blood flow waveform measurements: study on variability within and between day during haemodynamic intervention in normal subjects. Eur J Clin Pharmacol 41: 125–129

    Google Scholar 

  20. MacDonald NJ, Butters L, O'Shaughnessy DJ, Riddell AJ, Rubin PC (1989) A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man. Br J Clin Pharmacol 28: 257–261

    Google Scholar 

  21. Gosling RG, King DH (1974) Continuous wave ultrasound as an alternative and complement to X-rays in vascular examinations. In: Reneman RS (ed) Cardiovascular applications of ultrasound. North-Holland, Amsterdam, pp 266–282

    Google Scholar 

  22. Burns PN (1987) The physical principles of Doppler and spectral analysis. J Clin Ultrasound 15: 567–590

    Google Scholar 

  23. Kindman LA, Kates RE, Ginsburg R (1991) Opioids potentiate contractile response of rabbit myocardium to the beta adrenergic agonist isoproterenol. J Cardiovasc Pharmacol 17: 61–67

    Google Scholar 

  24. Wright DM, Clarke G (1986) Inhibitory effect of U-50488H on suckling-evoked oxytocin release is blocked by propranolol. Br J Pharmacol 89: 646P

  25. Clarke G, Wright DM (1986) Do mu- and kappa- selective opioids inhibit oxytocin release in the same way? Br J Pharmacol Proc Suppl 89: 758P

  26. Ensinger H, Hedler L, Schnurr C, Starke K (1984) Ethylketocyclazocine decreases noradrenaline release and blood pressure in rabbit at a peripheral receptor. Naunyn Schmiedebergs Arch Pharmacol 328: 20–23

    Google Scholar 

  27. Ensinger H, Hedler L, Szabo B and Starke K (1986) Bremazocine causes sympatho-inhibition and hypotension in rabbits by activating peripheral K-receptors. J Cardiovasc Pharmacol 8: 470–475

    Google Scholar 

  28. Szabo B, Hedler L, Ensinger H, Starke K (1986) Opioid peptides decrease noradrenaline release and blood pressure in the rabbit at peripheral receptors. Naunyn Schmiedebergs Arch Pharmacol 329: 206–209

    Google Scholar 

  29. Starke K, Schoffel E, Illes P (1985) The sympathetic axons innervating the sinus node of the rabbit possess presynaptic opioid K- but not mu or delta-receptors. Naunyn Schmiedebergs Arch Pharmacol 329: 206–209

    Google Scholar 

  30. Roizen MF, Weisse V, Moss J, Kopin IJ (1975) Plasma catecholamines: arterial-venous differences and the influence of body temperature. Life Sci 16: 1133–1144

    Google Scholar 

  31. Esler MD, Hosking CJ, Willet IR, Leonard PW, Jennings GL (1985) Noradrenaline release and sympathetic nervous system activity. J Hypertens 3: 117–129

    Google Scholar 

  32. Goldstein DS, McCarty R, Polinsky RJ, Kopin IJ (1983) Relationship between plasma noradrenaline and sympathetic neuronal activity. Hypertension 5: 552–559

    Google Scholar 

  33. Kunihara M, Ohyama M, Nakano M (1992) Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective kappa opioid receptor agonist. Eur J Pharmacol 214: 111–118

    Google Scholar 

  34. Best JD, Halter JB (1982) Release and clearance rates of epinephrine in man: importance of arterial measurements. J Clin Endocrinol Metab 55: 263–268

    Google Scholar 

  35. Blackburn TP, Borkowski KR, Friend J, Rance MJ (1986) On the mechanisms of K-opioid induced diuresis. Br J Pharmacol 89: 593–598

    Google Scholar 

  36. Borkowski KR (1989) Studies on the adrenomedullary dependence of K-opioid agonist-induced diuresis in conscious rats. Br J Pharmacol 98: 1151–1156

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Therapeutics, Queen's Medical Centre, Nottingham, UK

    G. H. Rimoy, N. K. Bhaskar & P. C. Rubin

  2. Upjohn Limited, Crawley, West Sussex, UK

    D. M. Wright

Authors
  1. G. H. Rimoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. M. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. K. Bhaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. C. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rimoy, G.H., Wright, D.M., Bhaskar, N.K. et al. The cardiovascular and central nervous system effects in the human of U-62066E. Eur J Clin Pharmacol 46, 203–207 (1994). https://doi.org/10.1007/BF00192549

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00192549

Key words

Search

Navigation